ArticleMedComm2023

Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma.

Yali Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.